Epigenetic siRNA and Chemical Screens Identify SETD8 Inhibition as a Therapeutic Strategy for p53 Activation in High-Risk Neuroblastoma
Veronica Veschi(Sapienza University of Rome), Carol J. Thiele(National Cancer Institute), C.H. Arrowsmith(University Health Network), Giuseppe Giannini(Istituto Pasteur), Laurent Ozbun(National Cancer Institute), Javed Khan(Kent State University), Gordon L. Hager(National Institutes of Health), Bárbara Kunzler Souza(Universidade Federal do Rio Grande do Sul), Jian Jin(Icahn School of Medicine at Mount Sinai), Ying Hu(Fujian Agriculture and Forestry University), Ettore Appella(National Institutes of Health), Sharlyn J. Mazur(National Institutes of Health), Norris Lam(National Institutes of Health), Berkley E. Gryder(University School), Zhihui Liu(Jilin University), Anqi Ma(Icahn School of Medicine at Mount Sinai), Ty C. Voss(National Cancer Institute), Chunhua Yan(National Cancer Institute)
Cited by 128
Related Papers
Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks
|Nature Medicine|2001|2.7k
Epigenetic protein families: a new frontier for drug discovery
|Nature Reviews Drug Discovery|2012|1.3k
DNA damage activates p53 through a phosphorylation–acetylation cascade
|Genes & Development|1998|1.2k
The promise and peril of chemical probes
|Nature Chemical Biology|2015|848